Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH)
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2018
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational
- Acronyms PATENT-CHILD
- Sponsors Bayer HealthCare
- 22 Feb 2018 Planned End Date changed from 12 Jun 2020 to 25 Nov 2031.
- 22 Jan 2018 Planned number of patients changed from 20 to 23.
- 22 Jan 2018 Planned End Date changed from 28 Dec 2020 to 12 Jun 2020.